Medication development in opioid addiction: Meaningful clinical end points
- PMID: 29593105
- DOI: 10.1126/scitranslmed.aan2595
Medication development in opioid addiction: Meaningful clinical end points
Abstract
The FDA's "abstinence" outcome measure for approval of new medications to treat opioid-use disorders has been difficult to achieve; developing and validating alternative meaningful outcomes could facilitate drug development.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical